SCHEMBL3021806

SCHEMBL3021806

CC(C)CC[CH]N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11213505 0.79
SCHEMBL10392314 0.77 LMNA (0.43)
SCHEMBL447993 0.75
SCHEMBL7995031 0.72 LMNA (0.35)
SCHEMBL2840987 0.72 LMNA (0.35)
SCHEMBL38852 0.69
SCHEMBL8076785 0.69
SCHEMBL19817574 0.67
SCHEMBL72618 0.67
SCHEMBL107778 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106892855-A New compound, color dispersion liquid, colored curable resin composition, colour filter and display device 东友精细化工有限公司 2017-06-27 CN disclosed
CN-103524392-A Azetidines as mek inhibitors for the treatment of proliferative diseases EXELIXIS INC 2014-01-22 CN disclosed
CN-101365676-B Azetidines as mek inhibitors for the treatment of proliferative diseases EXELIXIS INC 2013-09-11 CN disclosed
CN-1810802-B 3-substituted-4-pyrimidone derivatives MITSUBISHI PHARMA CORP 2011-04-27 CN disclosed
CN-1726209-B 3-substituted-4-pyrimidone derivatives SANOFI AVENTIS 2011-04-13 CN disclosed
EP-1745002-B1 NOVEL COMPOUNDS, THEIR PREPARATION AND USE HIGH POINT PHARMACEUTICALS LLC (US) 2010-11-03 EP disclosed
US-20100210653-A1 Novel Compounds, Their Preparations and Use HIGH POINT PHARMACEUTICALS, LLC (US) 2010-08-19 US disclosed
CN-1764650-B 2, 3, 6-trisubstituted-4-pyrimidone derivatives MITSUBISHI PHARMA CORP 2010-06-16 CN disclosed
CN-100488958-C 3-substituted-4-pyrimidone derivatives MITSUBISHI PHARMA CORP SANOFI (JP) 2009-05-20 CN disclosed
CN-101365676-A Azetidines as mek inhibitors for the treatment of proliferative diseases EXELIXIS INC (US) 2009-02-11 CN disclosed
EP-1745002-A1 NOVEL COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2007-01-24 EP disclosed
CN-1810802-A 3-substituted-4-pyrimidone derivatives MITSUBISHI PHARMA CORP (JP) 2006-08-02 CN disclosed
CN-1764650-A 2, 3, 6-trisubstituted-4-pyrimidone derivatives MITSUBISHI PHARMA CORP (JP) 2006-04-26 CN disclosed
CN-1726209-A 3-substituted-4-pyrimidone derivatives SANOFI AVENTIS (JP) 2006-01-25 CN disclosed
WO-2005105725-A1 NOVEL COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2005-11-10 WO disclosed
CN-1556804-A 3-substituted-4-pyrimidone derivatives ������ҩ��ʽ���� 2004-12-22 CN disclosed
CN-1555367-A 3-substituted-4-pyrimidone derivatives ������ҩ��ʽ���� 2004-12-15 CN disclosed
EP-0921122-B1 EPOXYSUCCINAMIDE DERIVATIVES OR SALTS THEREOF TAIHO PHARMACEUTICAL CO LTD (JP) 2003-05-21 EP disclosed
US-6110967-A USEFUL AS AGENTS FOR PREVENTING AND TREATING METABOLIC OSTEOPATHY SUCH AS OSTEOPOROSIS, HYPERCALCEMIA AND BONE METASTASIS OF CANCER BECAUSE THEY SPECIFICALLY INHIBITS CATHEPSIN L AND ITS FAMILY ENZYMES TO INHIBIT BONE RESORPTION TAIHO PHARMACEUTICALS CO., LTD. (JP) 2000-08-29 US disclosed
EP-0921122-A1 NOVEL EPOXYSUCCINAMIDE DERIVATIVES OR SALTS THEREOF TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) 1999-06-09 EP disclosed